Literature DB >> 8296483

Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.

E T Ben Ahmeida1, G Gregoriadis, C W Potter, R Jennings.   

Abstract

The immunogenicity and protective efficacy of an influenza A subunit vaccine preparation administered to mice in an aqueous form, or presented as immunostimulatory complexes (ISCOMs), liposomes or with Freund's complete adjuvant (FCA), were assessed in comparative studies with live infectious virus. Both intranasal and parenteral routes of administration were assessed. An enzyme-linked immunosorbent assay (ELISA) was used to measure nasal wash and serum antibody responses in groups of unprimed mice, while protection was determined by the recovery of homologous influenza virus from mouse nasal washes and lung homogenates following challenge infection by the intranasal route. The results showed that parenteral administration of the influenza antigen preparations induced variable levels of both local and systemic antibodies at weeks 3, 7 and 22 postimmunization. Although the overall greatest levels of antibody and protection were elicited in mice following live virus infection, formulation of influenza surface haemagglutinin (HA) and neuraminidase (NA) proteins into ISCOMs elicited high and persistent antibody responses and provided relatively good protection of the upper and lower respiratory tracts of these animals. The results also show a relatively poor effect of the subunit antigen preparations in promoting humoral immune responses and protection irrespective of the nature of their presentation, when given by the intranasal route.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296483     DOI: 10.1016/0264-410x(93)90099-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

Review 2.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

3.  Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

Authors:  Jun-Young Seo; Seung Yong Seong; Byung-Yoon Ahn; Ick Chan Kwon; Hesson Chung; Seo Young Jeong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 5.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

6.  Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.

Authors:  Felicity C Stark; Michael J McCluskie; Lakshmi Krishnan
Journal:  Vaccines (Basel)       Date:  2016-11-17

7.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.

Authors:  Krystyna Mozdzanowska; Darya Zharikova; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Virol J       Date:  2007-10-31       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.